USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OF STROKE OR TRANSIENT ISCHEMIC ATTACK
Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack.
1 . A method for preventing stroke or transient ischemic attack, in a patient in need thereof, comprising administering to the patient an effective dose of dronedarone.
2 . The method according to claim 1 for preventing stroke.
3 . The method according to claim 1 for preventing about 35% of stroke.
4 . The method according to claim 1 , wherein the patient has a history of, or a current atrial fibrillation or atrial flutter.
5 . The method according to claim 1 , wherein the patient has at least one of the following risk factors:
age,
hypertension,
diabete,
prior cerebrovascular accident or systemic embolism,
left atrium diameter greater that or equal to 50 mm by echocardiography,
left ventricular ejection fraction less than 40% by 2D-echocardiography.
6 . The method according to claim 1 , wherein the patient has additional risk factors corresponding to at least one of the following diseases:
hypertension,
structural heart disease,
tachycardia,
coronary heart disease,
non-rheumatic valvular heart disease,
ischemic dilated cardiomyopathy,
ablation for AF/AFL,
supra-ventricular tachycardia other than AF/AFL,
history of cardiac valve surgery,
non-ischemic dilated cardiomyopathy,
hypertrophic cardiomyopathy,
rheumatic valvular heart disease,
sustained ventricular tachycardia,
congenital heart disease,
ablation for other reason than AF/AFL,
ventricular fibrillation,
or at least a cardiac device chosen among:
a pacemaker,
an implanted cardioverter defibrillator.
7 . The method according to claim 1 , wherein for oral administration, dronedarone daily dose may reach 800 mg.
8 . A method for preventing acute coronary syndrome, in a patient in need thereof, comprising administering to the patient an effective dose of dronedarone.
9 . The method according to claim 8 , wherein the patient has a history of, or a current atrial fibrillation or atrial flutter.
10 . The method according to claim 8 , wherein the patient has at least one of the following risk factors:
age,
hypertension,
diabete,
prior cerebrovascular accident or systemic embolism,
left atrium diameter greater that or equal to 50 mm by echocardiography,
left ventricular ejection fraction less than 40% by 2D-echocardiography.
11 . The method according to claim 7 , wherein the patient has additional risk factors corresponding to at least one of the following diseases:
hypertension,
structural heart disease,
tachycardia,
coronary heart disease,
non-rheumatic valvular heart disease,
ischemic dilated cardiomyopathy,
ablation for AF/AFL,
supra-ventricular tachycardia other than AF/AFL,
history of cardiac valve surgery,
non-ischemic dilated cardiomyopathy,
hypertrophic cardiomyopathy,
rheumatic valvular heart disease,
sustained ventricular tachycardia,
congenital heart disease,
ablation for other reason than AF/AFL,
ventricular fibrillation,
or at least a cardiac device chosen among:
a pacemaker,
an implanted cardioverter defibrillator.
12 . A method for preventing fatal stroke, in a patient in need thereof, comprising administering to the patient an effective dose of dronedarone.
13 . The method according to claim 12 , wherein the patient has a history of, or a current atrial fibrillation or atrial flutter.
14 . The method according to claim 12 , wherein the patient has at least one of the following risk factors:
age,
hypertension,
diabete,
prior cerebrovascular accident or systemic embolism,
left atrium diameter greater that or equal to 50 mm by echocardiography,
left ventricular ejection fraction less than 40% by 2D-echocardiography.
15 . The method according to claim 12 , wherein the patient has additional risk factors corresponding to at least one of the following diseases:
hypertension,
structural heart disease,
tachycardia,
coronary heart disease,
non-rheumatic valvular heart disease,
ischemic dilated cardiomyopathy,
ablation for AF/AFL,
supra-ventricular tachycardia other than AF/AFL,
history of cardiac valve surgery,
non-ischemic dilated cardiomyopathy,
hypertrophic cardiomyopathy,
rheumatic valvular heart disease,
sustained ventricular tachycardia,
congenital heart disease,
ablation for other reason than AF/AFL,
ventricular fibrillation,
or at least a cardiac device chosen among:
a pacemaker,
an implanted cardioverter defibrillator.
16 . The method according to claim 12 , wherein for oral administration, dronedarone daily dose may reach 800 mg.
17 . A method for preventing stroke, in a patient in need thereof, comprising administering to the patient an effective dose of dronedarone or one of its pharmaceutically acceptable salts.